C
JANX icon

Covestor’s Janux Therapeutics JANX Stock Holding History

Covestor’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
29
+21
+263% +$304 ﹤0.01% 2656
2026
Q1 		$0 Buy
8
+5
+167% +$69 ﹤0.01% 2524
2025
Q4 		$0 Hold
3
– – ﹤0.01% 2497
2025
Q3 		$0 Hold
3
– – ﹤0.01% 2513
2025
Q2 		$0 Hold
3
– – ﹤0.01% 2465
2025
Q1 		$0 Hold
3
– – ﹤0.01% 2472
2024
Q4 		$0 Hold
3
– – ﹤0.01% 2481
2024
Q3 		$0 Hold
3
– – ﹤0.01% 2463
2024
Q2 		$0 Buy
+3
New +$141 ﹤0.01% 2482

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Covestor's JANX Position: Q2 2026 in Review

Covestor increased its Janux Therapeutics (JANX) stake by 263% in Q2 2026, buying an estimated $304 and bringing the position to 29 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2656.

Covestor first reported a position in JANX in Q2 2024 and has held it in 9 quarters since. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Covestor held 29 shares of Janux Therapeutics worth $0 as of Q2 2026.
  • Covestor bought 21 Janux Therapeutics shares in Q2 2026, an estimated $304.
  • Janux Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2656 holding.
  • Covestor first reported a position in Janux Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.